ExonHit launches Alzheimer's blood test for research use
This article was originally published in Clinica
Executive Summary
ExonHit Therapeutics has launched its Alzheimer’s blood test, AclarusDx. The product is now available for research use only for pharmaceutical companies and academic centres conducting clinical trials in the disorder. ExonHit (Paris, France) will process blood samples at its GLP-compliant labs in the US. The company plans to CE mark the test for sale in Europe in the fourth quarter of 2010, with a European launch following in the first quarter of 2011. AclarusDx analyses whether messenger RNA from a patient's blood sample matches a molecular profile that is specific to Alzheimer's disease.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.